{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:20:09Z","timestamp":1793830809288,"version":"4.6.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01423-5","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T03:13:44Z","timestamp":1763954024000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world decline in survival with poor guideline adherence in chronic myeloid leukemia care"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8249-9285","authenticated-orcid":false,"given":"Sanne J. J. P. M.","family":"Metsemakers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve I. C. G.","family":"Ector","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4767-6716","authenticated-orcid":false,"given":"Avinash G.","family":"Dinmohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosella P. M. G.","family":"Hermens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M. A.","family":"Blijlevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"1423_CR1","first-page":"3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood J Am Soc Hematol. 2000;96:3343\u201356.","journal-title":"Blood J Am Soc Hematol"},{"key":"1423_CR2","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1002\/cncr.26679","volume":"118","author":"X Huang","year":"2012","unstructured":"Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012;118:3123\u20137.","journal-title":"Cancer"},{"key":"1423_CR3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00277-015-2314-2","volume":"94","author":"M H\u00f6glund","year":"2015","unstructured":"H\u00f6glund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol. 2015;94:241\u20137.","journal-title":"Ann Hematol"},{"key":"1423_CR4","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.clml.2015.08.088","volume":"15","author":"SL Goldberg","year":"2015","unstructured":"Goldberg SL. Monitoring chronic myeloid leukemia in the real world: gaps and opportunities. Clin Lymphoma Myeloma Leuk. 2015;15:711\u20134.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1423_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","volume":"22","author":"NP Shah","year":"2024","unstructured":"Shah NP, Ravia B, Altman JK, Amaya M, Begna KH, Berman E, et al. Chronic myeloid leukemia, version 2.2024, nccn clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2024;22:43\u201369.","journal-title":"J Natl Compr Cancer Netw"},{"key":"1423_CR6","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia"},{"key":"1423_CR7","doi-asserted-by":"publisher","first-page":"e486","DOI":"10.3324\/haematol.2017.175265","volume":"102","author":"IG Geelen","year":"2017","unstructured":"Geelen IG, Thielen N, Janssen JJWM, Hoogendoorn M, Roosma TJA, Willemsen SP, et al. Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survival. Haematologica. 2017;102:e486.","journal-title":"Haematologica"},{"key":"1423_CR8","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.3324\/haematol.2017.174953","volume":"102","author":"IG Geelen","year":"2017","unstructured":"Geelen IG, Thielen N, Janssen JJWM, Hoogendoorn M, Roosma TJA, Willemsen SP, et al. Treatment outcome in a population-based,\u2018real-world\u2019cohort of patients with chronic myeloid leukemia. Haematologica. 2017;102:1842.","journal-title":"Haematologica"},{"key":"1423_CR9","doi-asserted-by":"publisher","first-page":"e039770","DOI":"10.1136\/bmjopen-2020-039770","volume":"11","author":"M Nothacker","year":"2021","unstructured":"Nothacker M, Bolster M, Steudtner M, Arnold K, Deckert S, Becker M, et al. International experiences in the development and implementation of guideline-based quality indicators: a qualitative study. BMJ Open. 2021;11:e039770.","journal-title":"BMJ Open"},{"key":"1423_CR10","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1080\/10428194.2022.2142055","volume":"64","author":"GICG Ector","year":"2023","unstructured":"Ector GICG, Geelen IGP, Dinmohamed AG, Hoogendoorn M, Westerweel PE, Hermens RPMG, et al. Adherence to quality indicators in chronic myeloid leukemia care: results from a population-based study in The Netherlands. Leukemia Lymphoma. 2023;64:424\u201332.","journal-title":"Leukemia Lymphoma"},{"key":"1423_CR11","unstructured":"IKNL. Nederlandse Kankerregistratie - Dutch Cancer Registration. https:\/\/iknl.nl\/nkr. Accessed June 2023."},{"key":"1423_CR12","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1185\/03007995.2013.812034","volume":"29","author":"SL Goldberg","year":"2013","unstructured":"Goldberg SL, Chen L, Guerin A, Macalalad AR, Liu N, Kaminsky M, et al. Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib. Current Med Res Opin. 2013;29:1075\u201382.","journal-title":"Current Med Res Opin"},{"key":"1423_CR13","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1002\/ajh.24887","volume":"92","author":"SL Goldberg","year":"2017","unstructured":"Goldberg SL, Cortes JE, Gambacorti-Passerini C, Hehlmann R, Khoury HJ, Michallet M, et al. First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol. 2017;92:1214\u201323.","journal-title":"Am J Hematol"},{"key":"1423_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/bjh.16733","volume":"192","author":"D Milojkovic","year":"2021","unstructured":"Milojkovic D, Cross NCP, Ali S, Byrne J, Campbell G, Dignan FL, et al. Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. Br J Haematol. 2021;192:62\u201374.","journal-title":"Br J Haematol"},{"key":"1423_CR15","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1185\/03007995.2013.858621","volume":"30","author":"MN Saleh","year":"2014","unstructured":"Saleh MN, Haislip S, Sharpe J, Hess T, Gilmore J, Jackson J, et al. Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community setting. Curr Med Res Opin. 2014;30:529\u201336.","journal-title":"Curr Med Res Opin"},{"key":"1423_CR16","first-page":"640","volume":"37","author":"D Rizzieri","year":"2012","unstructured":"Rizzieri D, Moore JO. Implementation of management guidelines for chronic myeloid leukemia: perspectives in the United States. Pharm Ther. 2012;37:640\u20138.","journal-title":"Pharm Ther"},{"key":"1423_CR17","doi-asserted-by":"publisher","first-page":"5261","DOI":"10.1002\/cncr.26196","volume":"117","author":"A Quint\u00e1s-Cardama","year":"2011","unstructured":"Quint\u00e1s-Cardama A, Cortes JE, Kantarjian HM. Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase. Cancer. 2011;117:5261\u201370. https:\/\/doi.org\/10.1002\/cncr.26196.","journal-title":"Cancer"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01423-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01423-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01423-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T15:07:26Z","timestamp":1763996846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01423-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1423"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01423-5","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study\u2019s design, data collection, analysis, and interpretation were independent of any involvement or influence from funding bodies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Data was obtained from the Netherlands Cancer Registry (NCR), maintained by the Netherlands Comprehensive Cancer Organization (IKNL), which collects data from Dutch hospitals [11]. As this study used registry data, patient consent was not required. The NCR provides data exclusively for scientific research and statistical purposes, in accordance with contractual agreements with contributing hospitals. Before receiving the data, we submitted a data request to the NCR. This request was reviewed and approved by both the NCR\u2019s ethical board and scientific committee. The NCR then provided anonymized data to us within a secure data environment. The IKNL\/NCR handles patient data in full compliance with the General Data Protection Regulation (GDPR) and all other applicable legal and regulatory requirements. As such, for the present study, approval by an ethics committee and informed patient consent were not required since we used registry data. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval And Consent To Participate"}},{"value":"During the preparation of this work the authors used AI to improve language and readability only. After using this service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies in the writing process"}}],"article-number":"205"}}